A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: movies (2), pictures (143)

PEEER newsletter February 2020

Description
February 2020 Edition Southampton’s City Nuffield Theatre Thursday 12th of March 2020 Arrival from 6.30pm The evening will include: Buffet
Url
/Media/UHS-website-2019/Docs/Services/Child-health/Ready-Steady-Go/PEEER-newsletter-February-2020.pdf

Ponatinib

Description
Chemotherapy Protocol Chronic Myeloid Leukaemia Ponatinib All licensed indications are not funded therefore an application for funding is required before prescribing
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Ponatinib.pdf

Facial nerve palsy - patient information

Description
This factsheet explains what facial nerve palsy is and how it is treated.
Url
/Media/UHS-website-2019/Patientinformation/Eyes/Facial-nerve-palsy-1912-PIL.pdf

Capecitabine-TrastuzumabIV-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine–Trastuzumab (IV)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (IV)-Tucatinib Indication t • Treatment of over-expressed
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-IV-Tucatinib.pdf

Capecitabine-Trastuzumab-SC-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib Indication • Treatment of over-expressed HER2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

Laboratory medicine user handbook rev 22

Description
University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.7 Laboratory Medicine user handbook rev 22 G3.7 Laboratory Medicine Laboratory
Url
/Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Laboratory-medicine-user-handbook.pdf

Enzalutamide

Description
Chemotherapy Protocol PROSTATE ENZALUTAMIDE Regimen • Prostate-Enzalutamide Indication • Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Enzalutamide.pdf

VenetoclaxLow

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

Chlorambucil_7day

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (7 day) There are several versions of this protocol each using a different dose or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7day.pdf
11 to 20 of 103
Previous 1 2 3 4 5 … Next